Tag: interim report

A webinar on the presentation of the results (in Estonian only) will take place on 31 July at 13:00 (EEST), more information.

Sales Revenues and Profitability

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI^®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

AB Ignitis grupė (hereinafter – the Group) will release its 6M 2025 results on Wednesday, 13 August 2025. It will be followed by an earnings call for investors and analysts to be held on the same day at 1:00 pm Vilnius / 11:00 am London time.

AB Ignitis grupė (hereinafter – the Group) will release its 6M 2025 results on Wednesday, 13 August 2025. It will be followed by an earnings call for investors and analysts to be held on the same day at 1:00 pm Vilnius / 11:00 am London time.